The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.
Onyema Ogbuagu, MBBCh, FACP, FIDSA
Advertisement
Associate Professor of Medicine (AIDS) and of Pharmacology, Yale
Principal investigator, PURPOSE 2
Articles by Onyema Ogbuagu, MBBCh, FACP, FIDSA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
2
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
3
GLP-1 Receptor Agonists May Improve Rheumatoid Arthritis Symptoms
4
Elinzanetant Shows Strong 52-Week Safety for Vasomotor Symptoms: James Simon, MD
5
